期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 8, 期 4, 页码 413-417出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.6b00496
关键词
LMP2; immunoproteasome; constitutive proteasome; beta 1i; beta lc
Building upon the success of bortezomib (VELCADE) and carfilzomib (KYPROLIS), the design of a next generation of inhibitors targeting specific subunits within the immunoproteasome is of interest for the treatment of autoimmune disease. There are three catalytic subunits within the immunoproteasome (low molecular mass polypeptide-7, -2, and multicatalytic endopeptidase complex subunit-1; LMP7, LMP2, and MECL-1), and a campaign was undertaken to design a potent and selective LMP2 inhibitor with sufficient properties to allow far sustained inhibition in vivo. Screening a focused library of epoxyketones revealed a series of potent dipeptides that were, optimized to provide the highly selective inhibitor KZR-504 (12).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据